Lunai Bioworks (NASDAQ:LNAI) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Lunai Bioworks (NASDAQ:LNAI) from a hold rating to a sell rating in a report released on Sunday morning.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lunai Bioworks in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Lunai Bioworks Stock Performance

Shares of Lunai Bioworks stock opened at $0.89 on Friday. Lunai Bioworks has a 1 year low of $0.81 and a 1 year high of $14.00. The stock has a market cap of $20.75 million, a P/E ratio of -12.65 and a beta of 0.37. The business has a 50-day simple moving average of $1.09.

Lunai Bioworks (NASDAQ:LNAI) last posted its quarterly earnings results on Friday, November 14th. The company reported $0.13 earnings per share for the quarter.

Hedge Funds Weigh In On Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC bought a new stake in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks at the end of the most recent quarter. 71.41% of the stock is owned by institutional investors.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.